Oxigene To Acquire Vaxgen In Stock Swap | October 26, 2009 Issue - Vol. 87 Issue 43 | Chemical & Engineering News
Volume 87 Issue 43 | p. 17 | Concentrates
Issue Date: October 26, 2009

Oxigene To Acquire Vaxgen In Stock Swap

Department: Business
Keywords: vaccines, biopharmaceuticals

Oxigene, a biopharmaceutical company developing treatments for cancer and eye diseases, will acquire VaxGen, a biopharmaceutical firm with cell culture and microbial biologic production expertise, in an exchange of common stock. The deal will give Oxigene a cash infusion of about $33 million. VaxGen suffered a setback in 2006 when it lost an $878 million contract to manufacture 75 million doses of an anthrax vaccine for the U.S. government.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment